Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve outcomes of patients with type 2 diabetes at high cardiovascular risk and chronic kidney disease. Recent studies showed an increase in hemoglobin and hematocrit after SGLT2i treatment.
Materials And Methods: We did a systematic review and meta-analysis of randomized, double-blind, placebo-controlled studies of SGLT2i in patients with type 2 diabetes. We searched through PubMed/Medline, Web of Science, Embase (Elsevier), and the Cochrane Central Register of Controlled Trials (Wiley) from January 2010 to January 2021.
Results: We included seventeen randomized, double-blind, placebo-controlled studies. The total number of evaluated patients was 14,748. The treatment arm consisted of canagliflozin, dapagliflozin, empagliflozin and ipragliflozin. SGLT2i therapy significantly increased hemoglobin levels when compared to placebo (MD 5.60 g/L, 95% CI 3.73-7.47 g/L, P < 0.00001, considerable heterogeneity-I = 94%). Each SGLT2i also led to a significant increase in the hematocrit level when compared to placebo (MD 1.32%, 95% CI 1.21-1.44, P < 0.00001, considerable heterogeneity-I = 99%).
Conclusions: SGLT2i led to significant increases in hemoglobin and hematocrit levels when compared to placebo. In addition to their cardiovascular effect, SGLT2i also increases hemoglobin and hematocrit levels.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11255-021-02943-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of Different Intervention Modes in Lifestyle Intervention for the Prevention of Type 2 Diabetes and the Reversion to Normoglycemia in Adults With Prediabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
J Med Internet Res
January 2025
School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Background: Lifestyle interventions have been acknowledged as effective strategies for preventing type 2 diabetes mellitus (T2DM). However, the accessibility of conventional face-to-face interventions is often limited. Digital health intervention has been suggested as a potential solution to overcome the limitation.
View Article and Find Full Text PDFBackground And Aim: There is paucity of data about the prevalence of cirrhosis and portal hypertension in the US general population.
Methods: We used National Health and Nutrition Examination Surveys (NHANES 2017-2020) to estimate the prevalence of cirrhosis and clinically significant (CS)-portal hypertension in alcoholic liver disease (ALD), MetALD, viral hepatitis (VH) to include chronic hepatitis B (CHB) and chronic hepatitis C (CHC), and metabolic dysfunction-associated steatotic liver disease (MASLD). Cirrhosis was evaluated using liver stiffness measurement (LSM) by transient elastography or FIB-4 score; CS-portal hypertension was defined via LSM and platelet count or the use of non-selective beta-blockers in the presence of cirrhosis.
Coordination of care in health systems for users with diabetes and hypertension: a scoping review.
Rev Lat Am Enfermagem
January 2025
Universidade de Brasília, Brasília, DF, Brazil.
Objective: to map the available evidence on the characteristics of care coordination between Primary Health Care and Specialized Outpatient Care for users with diabetes and hypertension.
Method: this is a scoping review with 40 articles as the final sample, evaluated by means of Content Analysis, of the thematic-categorical type, with the aid of a technological tool.
Results: care coordination was defined by means of eight categories: information and communication, integration of care, improvement and quality, care management, care sharing, fundamental attribute, health professionals and health service users, with the results of the articles concentrating mainly on four categories, with information and communication standing out, followed by the category of care management and the category of care sharing, in parallel with improvement and quality.
Islet Autoantibody Screening Throughout Australia Using In-Home Blood Spot Sampling: 2-Year Outcomes of Type1Screen.
Diabetes Care
January 2025
Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Objective: Type1Screen offers islet autoantibody testing to Australians with a family history of type 1 diabetes (T1D) with the dual aims of preventing diabetic ketoacidosis (DKA) and enabling use of disease-modifying therapy. We describe screening and monitoring outcomes 2 years after implementing in-home capillary blood spot sampling.
Research Design And Methods: Data from 2,064 participants who registered between July 2022 and June 2024 were analyzed: 1,507 and 557 chose blood spot and venipuncture screening respectively.
New Therapeutic Perspectives in Type B Insulin Resistance Syndrome: Efficacy of a Multitarget Therapy With Obinutuzumab and Mycophenolate Mofetil in Two Patients With Insulin Receptor Autoantibodies and Systemic Lupus Erythematosus.
Diabetes Care
January 2025
Hôpital Saint-Antoine, Centre de Référence des Maladies Rares de l'Insulino-Sécrétion et de l'Insulino-Sensibilité (PRISIS), Service d'Endocrinologie, Assistance Publique-Hôpitaux de Paris, Paris, France.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!